Why CDK4/6 Inhibitors Are Effective in HR-Positive Metastatic Breast Cancer

Videos

Featuring:

Dr Hope Rugo cites that CDK4/6 inhibitors play a critical role in estrogen signaling and can be very effective in treating metastatic breast cancer when used in combination with hormone therapy.

Want more Breast Cancer-related news?

Sign up for the OPM weekly e-Newsletter!

Enter your contact information below to recieve weekly oncology news & updates.

Related Articles

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to recieve the free OPM print publications or weekly e‑Newsletter.

I'd like to recieve: